The IMiD lenalidomide has shown promising results as a single agent 16 as well as in combination with other active agents for the treatment of MM. 15, 17, 18, 19, 20 ...

Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study. This is an ASCO Meeting ...

As effects of glucocorticoids differ with respect to preparation, dose and duration, we hypothesized that a postnatal regimen of a low-dose, short-course betamethasone treatment had comparable ...

Author(s)Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ...

Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).

Acute COVID-19 illness complications include stroke, encephalopathies, neuropsychiatric and inflammatory syndromes, whereas non-severe cases may suffer from ...

A dexamethasone-sparing regimen of daratumumab and lenalidomide was safe and effective in older, frail patients with newly diagnosed multiple myeloma. Among that select group of patients, ...

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and effective in older, frail patients with newly diagnosed multiple myeloma, ...